New drug cocktail shows promise in slowing uterine cancer before surgery
NCT ID NCT04049227
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested two drugs, abemaciclib and letrozole, given before standard hysterectomy in 27 women with endometrial cancer. The goal was to see if the combination could slow cancer cell growth by measuring changes in a protein called Ki-67. The study was small and focused on biological markers, not long-term outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
abemaciclib and letrozole
What this could lead to
If successful, this could point toward a new drug combination to slow endometrial cancer growth before surgery.
What could go wrong
This is a very early, small pilot study with only 27 participants. It only measures short-term biomarker changes, not long-term outcomes like survival or recurrence.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Northwestern University
Chicago, Illinois, 60611, United States
-
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, 60637, United States